In recent years, South China's Shenzhen has promoted the development of basic research platforms to aid in studies pertaining to brain science, precision medicine imaging, supercomputing, free electron laser, synchrotron radiation light source and material genome.
近年来，中国南方的深圳推动了基础研究平台的发展，以帮助脑科学、精准医学成像、超级计算、自由电子激光、同步辐射光源和材料基因组等研究。
As the company's highest-throughput, highest-capacity, and most sustainable high-throughput sequencer, this new product further reduces the cost of sequencing a single human whole genome from $600 to just $200.
作为该公司最高吞吐量、最高容量和最可持续的高通量测序仪，该新产品进一步将单个人类全基因组测序的成本从600美元降至200美元。
"NovaSeq X Plus will serve as a new benchmark in the field of genome sequencing, opening up broad application prospects for gene sequencing in China," Li said.
李说：“NovaSeq X Plus将成为基因组测序领域的新标杆，为基因测序在中国的应用开辟广阔前景。”。
But in early January 2020, the genome of the novel coronavirus was sequenced overnight by Chinese scientist Zhang Yongzhen, who used a sequencer made by Illumina.
但在2020年1月初，中国科学家张永珍使用Illumina制造的测序仪连夜对新型冠状病毒基因组进行了测序。
Shanghai-based molecular diagnostic information provider OrigiMed, together with scientists from several Chinese hospitals, announced the results of a study on the genomic characteristics of Asian cancer populations — the largest comprehensive genome analysis from tumor tissues and matched blood specimens of its kind so far, offering significant implications for clinical decision-making of precision medicine in China.
上海的分子诊断信息提供商OrigiMed与来自多家中国医院的科学家一起宣布了一项关于亚洲癌症人群基因组特征的研究结果，这是迄今为止对肿瘤组织和同类匹配血液样本进行的最大规模的综合基因组分析，为中国精准医疗的临床决策提供了重要启示。
Therefore, OrigiMed's study, as the largest comprehensive genome analysis of its kind so far, filled in the blank of the sector.
因此，OrigiMed的研究，作为迄今为止同类研究中规模最大的综合基因组分析，填补了该领域的空白。
NextSeq 2000 is the first sequencer developed by Illumina that integrates library amplification, sequencing, and rapid genome analysis on a single platform.
NextSeq 2000是Illumina开发的第一款测序仪，它将文库扩增、测序和快速基因组分析集成在一个平台上。
EdiGene is a biotech company developing genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases.
The Beijing-based company develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases.
"Tan Weijie, director-general of the Viral Disease Emergency Technology Center of the China Centers for Disease Control and Prevention, who led the completion of the world's first novel coronavirus isolation and genome sequencing identification, said accelerating technology innovation is of great strategic significance to China.
It has a diverse product and services portfolio in sectors that include clinical laboratory science and in vitro diagnostic medical devices and reagents, including an AI-based cancer genome data interpretation system and a fully closed, automated next-generation sequencing library-prep system.
The Beijing-based EdiGene Inc, which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced on Tuesday the successful completion of a 450 million yuan ($67 million) round of Series B financing.
The four platforms are ex vivo genome editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing and high-throughput genome-editing screening to discover novel targeted therapies.
"Recoding every protein in the human genome is a significant and difficult undertaking, requiring, for example, 400,000 changes," said Church.
"According to him, making large-scale changes to the genome could also help improve cellular survival by making cells less likely to become cancerous and to better resist damage from extreme conditions, such as radiation.
Now known as the Beijing Innovation Center, it is focused on world-leading genome editing research to support advanced plant breeding technologies for future farming.
Taking big data from the human genome to someone's epidemiology, and to other wearable sensors that may be picking up ongoing information about a patient, is going to dramatically change the way we think about drug discovery.
"The market is still in the early stages of genome sequencing services, but we feel the time is right to expand here.
"Genome sequencing data are widely used in key sectors such as agriculture, forensic science and clinical operation," he said.
"Part of Illumina's plan will be to team up with Chinese partners involved in genome sequencing services, such as DNA tracking, as the company looks to increase its global footprint.
"Startup companies in China's genome sequencing service sector are likely to benefit by using Illumina's resources," he said.
Its prowess in super computers also helped scientists from Saudi Arabia map the genome of the date-palm tree, whose fruit is a staple food in the region.
Sapientia analyzes a patient's entire genome, pinpointing mutations and generating rapid and accurate diagnosis of inherited diseases.
Professor Mark Caulfield, chief scientist at Genome England, told China Daily: "Genomics has the potential to transform healthcare, predicting how well a person will respond to a treatment or finding one that will work best for them.
"Genomics is at the crossroads where data and biology meet," said Li Ge, chairman of WuXi NextCODE and its parent WuXi AppTec Inc. "Through its comprehensive capabilities for digitizing, managing and analyzing genome data, WuXi NextCODE is positioned to build an open access and capability platform that enables any organization or individual to benefit from genomic big data," he said.
Ideally, gene sequencing can enable doctors to use a person's genome and physiology to determine the best treatments for a disease.
It can also provide drugs and treatment plans tailored to a person's unique genetic code and environmental exposure, said Xu Ruiqi, general-manager of BGI's Shanghai branch, a world-leading genome sequencer.
The outcome of genome sequencing showed the virus in that case has the same origin as the Alpha variant, a COVID-19 strain first detected in the United Kingdom.
Ma Yue and his colleagues from the Chinese Academy of Sciences used machine-learning techniques originally developed for natural language processing to identify antimicrobial peptides encoded by the genome sequences of microbes in the human gut.
Wei Dong, CEO of EdiGene, a Beijing-based private biotech company developing genome editing technologies, said talent－both locally grown, returnees from overseas－has contributed to the growing pharmaceutical industry's innovation capabilities.
This is especially the case for innovative biotech companies," said Wei Dong, CEO of Edi-Gene, a Beijing-based private biotech company developing genome editing technologies to accelerate drug discovery and develop novel therapeutics.
EdiGene Inc－a Beijing-based startup developing genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases－announced completion of a 450-million-yuan round of Series B financing in October.